IFNA16 (interferon alpha 16) is a type I interferon cytokine produced by immune cells that functions as a key mediator of antiviral and immunomodulatory responses. As a member of the interferon-alpha family, IFNA16 exerts its effects through type I interferon receptor binding and downstream type I interferon-mediated signaling pathways 1, activating both innate and adaptive immune responses including B cell, T cell, and natural killer cell activation 2. IFNA16 stimulates production of protein kinases and oligoadenylate synthetase, enzymatic components critical for antiviral defense mechanisms. Mechanistically, IFNA16 expression is dynamically regulated during HIV infection, with elevated levels observed in chr9 infected patients 3. Functionally, variant forms of IFNA16 retain comparable antiviral and STAT signaling profiles while exhibiting stage-restricted effects on interferon-regulated gene expression in megakaryocytes 4. IFNA16 polymorphisms demonstrate clinical relevance across multiple diseases: associations with melanoma susceptibility through immune cytokine signaling pathways 1, obstructive sleep apnea immune dysfunction 2, altered fatty acid composition in muscle tissue 5, modulation of platelet production in myeloproliferative neoplasms 4, and differential expression patterns in heart failure subtypes 6. Additionally, IFNA16 expression is reduced in acute HIV infection compared to chr9 infection, correlating with improved inflammatory control 7.